

Curriculum Vitae

MARIE-CLAUDE MONIER-FAUGERE, M.D.

I. General Information

Office Address: Division of Nephrology, Bone and Mineral Metabolism
Department of Internal Medicine
University of Kentucky
Lexington, KY 40536-0084

Office telephone: (859)-323-5049

II. Education

1966	Baccalaureate, Mathematics, France
1966-67	Pre-Medicine School Certificat Preparatoire aux Etudes Medicales Saint-Charles University and Medical School, Marseille, France
1967-73	Medical School, Faculte de Medecine de Marseille, France
1972-77	Residency (Internat des Hopitaux Universitaires de Marseille, France)
1974	Master in Human Biology
1977-78	Medaille d'Or-Internat des Hopitaux Universitaires de Marseille, France
1977	French Board of Pathology
1978	French Board of Neurology
1978	Medical Doctor Dissertation, France
1978	Diploma of studies and research in human biology/Neuropathology (DEA)

III-IV. Professional Experience and Academic Appointments

1975-78	Assistant Professor (part-time) Division of Neuropathology University of Marseille, France
1978-79	Assistant Professor Department of Pathology University of Marseille, France
1979-81	Assistant Professor Pathology and Neuropathology University of Marseille, France
June/1979	Visiting Scientist Institut Pasteur, Paris (Department of Immunology)
April/1980	Visiting Scientist Rothschild Foundation, Paris (Department of Pathology)
Oct. Nov./1980	Visiting Scientist Laboratoire d'Histodynamique osseuse

Feb.–
May/1981 Faculte Alexis Carrel, Lyon (Pr. P.J. Meunier)
Visiting Scientist
Laboratory of Bone Histomorphometry
Division of Nephrology, Department of Medicine
University of Southern Ca. School of Medicine
Los Angeles, California, USA

Jul.–
Aug./1981 Visiting Scientist
Laboratory of Bone Histomorphometry
University of Southern California

1981–1990 Research Scientist
Division of Nephrology, Bone and Mineral Metabolism
Department of Medicine
University of Kentucky

1990–1998 Associate Research Professor
Internal Medicine and Pathology
University of Kentucky

1998–
Present Research Professor
Internal Medicine and Pathology
University of Kentucky

V. Hospital and Clinical Appointments:

1978–79 Hospital “La Conception”
University Hospital, Marseilles, France
Assistant Professor
Department of Pathology
Full time

1979–81 Hospital “La Timone”
University Hospital, Marseilles, France
Assistant Professor
Department of Pathology and Neuropathology
Full time

VI. Consulting activities

Ad Hoc Reviewer for National Institute of Aging at the NIH—STOP/IT program grant—
1991

Reviewer for Collier’s Encyclopedia—Metabolism and Metabolic Diseases—
Macmillan Educational Company, New York, NY

Member of Organizing Committee of the VIth International Congress on Bone
Morphometry, Lexington, KY, 1992—Chairperson of session on “Quality Control in Bone
Histology and Morphometry

Board of Directors of the International Society for Bone Morphometry—1992–present

Expert reviewer, Sanofi, France, Preclinical Trial Studies of Effect of Tiludronate on Bone—
Paris, France, 1997

Expert reviewer, INSERM Hopital Lariboisière–Saint Louis, Universite Paris 7, Paris, 1998

VII.–VIII. Teaching and Advising Activities

1981—Yvon Berlan, MD, Dissertation committee
Division of Nephrology
University of Marseilles, France

1982—Kay Lorentz
Histotechnician
Mayo Clinic, Rochester, MN

1984—Christine Schnitzler, MD
Professor of Orthopaedic Surgery
Johannesburg, South Africa

1985, 1989—Ilkka Arnala, MD, Visiting Scientist
Assistant Professor of Orthopaedic Surgery
Kuopio University, Kuopio, Finland

1986–1992—Benedek Bogнар, MD
Research Fellow/Consultant Radiologist
Semmelweis Medical University, Budapest, Hungary

1986–1988—Shao–xing Wu, MD
Physician of Nephrology
Sun Yat–Sen University, Guangzhou, China

1992, 1993—Robert Juvin, MD, Visiting Scientist
Department of Rheumatology
University of Grenoble, France

1990—Janet Rodgers, DVM
Assistant Research Professor of Plastic Surgery
University of Kentucky

1992—Gary Howath
Graduate Student, Department of Orthodontics
University of Kentucky

1993—Philip Wahle
Graduate Student, Department of Orthodontics
University of Kentucky

1992–1994—Pauling Chu, MD
Graduate Student, Department of Toxicology
University of Kentucky

1992–2001—Zhaopo Geng, MD
Research Fellow
Tianjan, PR China

1992—James Witfield, MS
Graduate Student, Gluck Equine Center
University of Kentucky

1992—Terry Horn, MD
Department of Biomechanics
University of Kentucky

1992—Elsie Barr, MS
Technologist
Lexington, KY

1992—V. Szjenfeld, MD
Research Scientist
Sao Paolo, Brazil

1992—Ian Watson, MS
Research Scientist
Perth, Australia

1992—Klaus Abendroth, MD
Innere Medizin
Jena, Germany

1993–2000—Quanle Qi, MD
Research Fellow
Tianjan, PR China

1996—Patricia Mandalunis, PhD
Research Associate
Buenos Aires, Argentina

1996—T.C. Chow, MS
Research Associate
Kowloon, Hong Kong

1997–98—Shawn M. Bader, DDM
Graduate Student
Department of Orthodontics
University of Kentucky

1998—Agnès LaLande, MS
Graduate Student
Universite Paris 7, France

2001— present Guadong Wang, MD
Post-Doctoral Fellow
University of Kentucky

2003— 2005 Nargis Hashem, MD
University of Kentucky

Charles Swanepoel, MD
2006
University of Cape Town
South Africa

2007-present Aziz Chami, MD
Fellow
University of Kentucky

Joon Lee, MD
2007-2008
University of Seoul, South Korea

Yilmaz Muntaz, MD
2008
University of Ismir, Turkey

Makoto Kajiwara
2008
Kureha Special Laboratory
Tokyo, Japan

IX. Administrative Activities:

Bone laboratory of the Division of Nephrology and Bone Mineral Metabolism and of the University of Kentucky General Clinical Research Center

Quality control for CAP accreditation

Past Board of Directors of International Society for Bone Morphometry

Assistant Editor, Clinical Nephrology

Research Subject Advocate of the University of Kentucky General Clinical Research Center 2002-2006

X. Special Assignments:

Organization of the committee on "Quality Control and Education of the International Society of Bone Morphometry"

Task force for implementation of HIPAA in research.

Committee for adverse events reporting

XI. Honors:

Medaille D'Or de L'Internat des Hopitaux de Marseille, 1978

Leon Isemein Research Awards, Marseille, 1981

XII. Professional Activities and Public Service:

Member:

American Society for Bone and Mineral Research
American Federation for Clinical Research
Ultrastructural Pathology Group, Paris
(Circle Francais de Pathologie Ultrastructurale, Paris)
French Society of Pathology
Neuropathology group (Club Francais de Neuropathologie)

Review panel for:

Bone
Bone and Mineral
Calcified Tissue International
Clinical Nephrology
Journal of Bone and Joint Surgery
Journal of Bone and Mineral Research
American Journal of Medicine
American Journal of Nephrology
American Journal of Pathology
Journal of Clinical Endocrinology and Metabolism
Kidney International
Mineral and Electrolyte Metabolism
New England Journal of Medicine
Nephrology, Dialysis and Transplantation
Nephron
J American College of Nutrition

XIII. Speaking Engagements:

4th Shriners Hospital for Crippled Children Annual Meeting, 1991, Chairperson, Anaheim, CA

Symposium on Undecalcified Bone Technology, Indianapolis, 1991
University of Grenoble, Renal Osteodystrophy Meeting, 1991
5th Shriners Hospital for Crippled Children Annual Meeting, 1992, Washington DC
Transport of Vitamin K and Its Action on Calcified Tissues, Berlin, Germany, 1992
Renal Osteodystrophy, Boston, ASN, 1993
Kidney Foundation, Atlanta, April 2000

XIV. Research Productivity:

Publications

Peer-reviewed articles

1. Pellissier, J.F., Hassoun, J., Faugere, M.C.: L'Histo-enzymologie en Pathologie Neuro-musculaire. *Prog. Med.* 102:323-330, 1974.
2. Papy, J.J., Conte-Devolx, J., Pellissier, J.F., Faugere, M.C., Corriol, J.: Etude experimentale de la conduction nerveuse et neuromusculaire au cours de la plongee fictive chez le chien et le lapin: correlations anatomo-pathologiques. *C.R. Soc. Biol.* 171:121-130, 1977.
3. Serratrice, G., Pellissier, J.F., Faugere, M.C., Gastaut, J.L.: Centronuclear myopathy: Possible central nervous system origin. *Muscle and Nerve* 1:62-78, 1978.
4. Berard-Badier, M., Pellissier, J.F., Faugere, M.C., Mouillac-Gambarelli, N., Berard, P.V., Toga, M.: Electron microscopy of extra-ocular muscles: subsarcolemmal granulo-fibrillar aggregates. *N. Neuro. Exp. Neuropathol.* 27:589, 1978.
5. Pellissier, J.F., de Barsey, T.H., Faugere, M.C., Rebuffel, P.: Type III glycogenosis with multi core disease. *Muscle and Nerve* 2:124-132, 1979.
6. Pellissier, J.F., Labreque, R., Faugere, M.C., Toga, M.: Leucoencephalopathie Multifocale Progressive et Hemochromatose. Etude anatomic d'une observation. *Arch. Anat. Cytol. Pathol.* 27:383-388, 1979.
7. Pellissier, J.F., Faugere, M.C., Gambarelli, D., Toga, M.: Les Paralysies Periodiques. Etude histologic, histochimique et ultrastructurale du muscle, a propos de cinq observations. *Arch. Anat. Cytol. Pathol.* 28:83-87, 1980.
8. Faugere, M.C., Mussini, J.M., Pellissier, J.F., Henin, D., Gray, F., Brousse, N.: Myosite a eosinophiles et syndrome de Shulman. *Arch. Anat. Cytol. Pathol.* 28:8387, 1980.
9. Choux, R., Pluot, M., Faugere, M.C., Rodriguez, M., Hassoun, J., Caulet, T.: Sarcome a cellulose claires des tendons et aponevroses. Etude de deux nouveaux cas en microscopie electronique. *Arch. Anat. Cytol. Path.* 28:203-206, 1980.
10. Charpin, C., Andrac, L., Faugere, M.C., Serment, G., Toga, M.: Tumor-like malacoplakia of the kidney. *Arch. Pathol. Lab. Med.* 104:611-612, 1980.

11. Acquiviva, P.C., Faugere, M.C., Ginsey, R., Serratrice, G.: Aspects radiologiques ducrane dans l'Hyperostose Vertebrale. *Rheumatology* 2:65–71, 1981.
12. Pellissier, J.F., Van Hoof, F., Bourdet–Bonnerandi, D., Faugere, M.C., Toga, M.: Morphological and biochemical changes in muscle and peripheral nerve in Fabry's Disease. *Muscle and Nerve* 4:381–387, 1981.
13. Devin, R., Branchereau, A., Pellissier, J.F., Faugere, M.C., Laselve, L., Toga, M.: Syndrome de compression du defile costo–claviculaire par tumeur de la premiere cote. *Chirurgie* 107:749–754, 1981.
14. Charpin, C., Andrac, L., Faugere, M.C., Hassoun, J., Cannoni, M., Vagneur, J.P.: Calcitonin, somatostatin and ACTH immunoreactive cells in a case of familial bilateral thyroid medullary carcinoma. *Cancer* 50:1806–1814, 1982.
15. Roux, H., Faulin, R., Vovan, L., Lanza, M., Fructus, X., Conti, V., Blachere, C., de Boissezon, M., Benvenuti, E., Faugere, M.C., Gaborit, P.: Dyslipidemie et osteonecrose hyperbare chez le rat. *Rev. Rhum.* 49:615–619, 1982.
16. Faugere, M.C., Malluche, H.H.: Comparison of different bone biopsy techniques for qualitative and quantitative diagnosis of metabolic bone diseases. *J. Bone Joint Surg.* 65A:1314–1319, 1983.
17. Dorr, L.D., Lindberg, J.P., Faugere, M.C., Malluche, H.H.: Factors influencing the intrusion of methylmethacrylate into human tibiae. *Clin. Orthop.* 132:147–152, 1984.
18. Malluche, H.H., Smith, A.J., Abreo, K., Faugere, M.C.: The use of desferrioxamine in the management of renal patients with bone aluminum accumulation. *N. Engl. J. Med.* 311:140–144, 1984.
19. Malluche, H.H., Faugere, M.C., Fanti, P., Price, P.A.: Plasma levels of bone Gla–protein reflect bone formation in patients on chronic maintenance dialysis. *Kidney Int.* 26:869–874, 1984.
20. Freundlich, M., Zilleruelo, G., Arbitbol, C., Strauss, J., Faugere, M.C., Malluche, H.H.: Infant formula as a cause of aluminum toxicity in neonatal uraemia. *Lancet* II:527–529 1985.
21. Malluche, H.H., Faugere, M.C.: Aluminum: toxin or innocent bystander in renal osteodystrophy? *Am. J. Kidney Dis.* 6:336–341, 1985.
22. Malluche, H.H., Faugere, M.C., Smith, A.J., Friedler, R.M.: Aluminum intoxication of bone in renal failure: fact or fiction? *Kidney Int.* 29, 70–73, 1986.
23. Faugere, M.C., Okamoto, S., DeLuca, H.F, Malluche, H.H.: Calcitriol corrects bone loss induced by oophorectomy in rats. *Am. J. Physiol.* 13:35–38, 1986.
24. Malluche, H.H., Faugere, M.C., Ritz, E., Caillens, G., Wildberger, D.: Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure. *Miner. Electrol. Metab.* 12:113–118, 1986.
25. Faugere, M.C., Arnala, I.O., Ritz, E., Malluche, H.H.: Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. *J. Lab. Clin. Med.* 107:481–487, 1986.

26. Smith, A.J., Faugere, M.C., Abreo, K., Fanti, P., Julian, B., Malluche, H.H.: Aluminum related bone disease in mild and advanced renal failure. *Am. J. Nephrol.* 6:275–283, 1986.
27. Faugere, M.C., Malluche, H.H.: Stainable aluminum and not aluminum content reflect histologic changes in bone of dialyzed patients. *Kidney Int.* 30:717–722, 1986.
28. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P., Friedler, R.M.: 1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. *Endocrinology* 119:1298–1304, 1986.
29. Freundlich, M., Abitbol, C., Faugere, M.C., Zilleruelo, G., Strauss, J., Malluche, H.H.: Treatment of aluminum toxicity with deferoxamine in infantile uremia. *J. Pediatr.* 109:140–143, 1986.
30. Malluche, H.H., Faugere, M.C., Rush, M., Friedler, R.M.: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. *Endocrinology* 119:2643–2654, 1986.
31. Malluche, H.H., Faugere, M.C., Fanti, P., Friedler, R.M.: Calcitriol, parathyroid hormone and the accumulation of aluminum in bone in dogs with renal failure. *J. Clin. Invest.* 79:754–761, 1987.
32. Julian, B.A., Faugere, M.C., Malluche, H.H.: Oxalosis in bone causing a radiographical mimicry of uremic osteodystrophy. *Am. J. Kidney Dis.* 9, No.5:436440, 1987.
33. Malluche, H.H., Faugere, M.C., Friedler, R.M., Fanti, P.: 1, 25Dihydroxyvitamin D₃ corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. *Endocrinology* 122: 1998–2006, 1988.
34. Malluche, H.H., Faugere, M.C., Arnala, I.: Noninvasive techniques for predicting bone histology. *Annales Chirurgiae et Gynaecologiae* 77:246–250, 1988.
35. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y., Malluche, H.H.: 1,25(OH)₂D₃ administration in moderate renal failure: A prospective double-blind trial. *Kidney Int.* 35:661–669, 1989.
36. Faugere, M.C., Friedler, R.M., Fanti, P., Malluche, H.H.: Bone changes occurring early after cessation of ovarian function in beagle dogs: A histomorphometric study employing sequential biopsies. *J. Bone Miner. Res.* 5(3):263–272, 1990.
37. Dorr, L.D., Arnala, I., Faugere, M.C., Malluche, H.H.: Preoperative systemic bone disease: Five year postoperative results of cemented femoral arthroplasty. *Clin. Orth. Rel. Res.* 259:114–121, 1990.
38. Malluche HH, Faugere MC: Risk of adynamic bone disease in dialyzed patients. *Kidney Int* 42 No. 4 (Suppl. 38): pp. 62–67, 1992.
39. Metsger, D.S., Arnala, I., Faugere, M.C., Malluche, H.H.: Histomorphometric analysis of tricalcium phosphate ceramic implanted into turkeys. *Bone* 14:243–248, 1993.
40. Rodgers, J.B., Faugere, M.C., Malluche, H.H.: Animal models for the study of bone loss after cessation of ovarian function. *Bone* 14:369–377, 1993.

41. Tsukamoto, Y., Mariyo, R., Nomura, Y., Sato, N., Faugere, M.C., Malluche, H.H.: Long-term effects of oral calcitriol pulse therapy on bone in hemodialysis patients. *Bone* 14:421–424, 1993.
42. Dorr, L., Faugere, M.C., Mackel, A., Gruen, T., Bognar, B., Malluche, H.H.: Structural and cellular assessment of bone quality of proximal femoral bone. *Bone* 14:231–242, 1993.
43. Monier–Faugere, M.C: Quality assurance–quality control in bone histopathology and bone histomorphometry. *Bone* 14:559–572, 1993.
44. John, J., Malluche, H.H., Faugere, M.C., Thoma, W., Kerschbaumer, F.: Compression fracture of a vertebral body after longterm ingestion of aluminum–containing antacid medication. *Osteologie Band 2, Heft 1*:41–45, 1993.
45. Monier–Faugere, M.C., Friedler, R.M., Bauss, F., Malluche, H.H.: A new bisphosphonate, BM21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. *J. Bone Miner. Res.* 8(11):1345–1355, 1993.
46. Malluche, H.H., Faugere, M.C.: The role of bone biopsy in the management of patients with renal osteodystrophy. *J. Amer. Soc. Nephrol.* 4(9):1641–1642, 1994.
47. Kurz, P., Monier–Faugere, M.C., Bognar, B., Werner, E., Roth, P., Vlachojannis, J., Malluche, H.H.: Calcium kinetics in patients with renal osteodystrophy. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. *Kidney Int.* 46:855–861, 1994.
48. Briner, V.A., Thiel, G., Monier–Faugere, M.C., Bognar, B., Landmann, J., Kamber, V., Malluche, H.H.: Prevention of osteopenia and evidence of renal bone disease two years after kidney transplantation. *Transplantation* 59:1393–1400, 1995.
49. Qi, Q., Monier–Faugere, M.C., Geng, Z., Malluche, H.H.: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. *Am. J. Kidney Dis.* 26:622–631, 1995.
50. Monier–Faugere, M.C., Geng, Z., Qi, Q., Arnala, I., Malluche, H.H.: Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs. *J. Bone Miner. Res.* 11(4):446–455, 1996.
51. Langub, M.C., Koszewski, N.J., Turner, H.V., Monier–Faugere, M.C., Geng, Z., Malluche, H.H.: Bone resorption and mRNA expression of IL–6 and IL–6 receptor in patients with renal osteodystrophy. *Kidney Int.* 50(2):515–520, 1996.
52. Sawaya, B.P., Koszewski, N.J., Qi, Q., Langub, M.C., Monier–Faugere, M.C., Malluche, H.H.: Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. *J. Am. Soc. Nephrol.* 8(2):271–278, 1997.
53. Szejnfeld, V.L., Monier–Faugere, M.C., Bognar, B.J., Ferraz, M.B., Malluche, H.H.: Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis. *J. Rheumatol.* 24:683–688, 1997.

54. Pienkowski, D., Doers, T.M., Monier–Faugere, M.C., Camacho, N.P., Boskey, A.L., Malluche, H.H.: Calcitonin alters bone quality in beagle dogs. *J. Bone Miner. Res.*, 12:1936–1943, 1997.
55. Fanti, P., Monier–Faugere, M.C, Geng, Z., Schmidt, J., Cohen, D., Malluche, H.H.: Moderately high consumption of ethanol suppresses histologic parameters of bone resorption in ovariectomized but not in sexually intact adult female rats. *Alcohol Clin. Exp. Res.* 2(6):1150–1154, 1997.
56. Rodgers, J.B., Vasconez, H.C., Wells, M.D., DeLuca, P.P., Faugere, M.C., Fink, B.F., Hamilton, D.: Two lyophilized polymer matrix rhBMP–2 carriers in rabbit calvarial defects. *J. Craniofacial Surg.* 9(2):147–153, 1998.
57. Fanti, P., Monier–Faugere, M.C., Geng, Z., Schmidt, J., Morris, P.E., Cohen, D., Malluche, H.H.: The phytoestrogen genistein reduces bone loss in short–term ovariectomized rats. *Osteoporosis Int* 8:274–281, 1998.
58. Monier–Faugere, M.C., Geng, Z., Friedler, R.M., Qi, Q., Kubodera, N., Slatopolsky, E., Malluche, H.H.: 22–Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int.* 55:821–832, 1999.
59. Monier–Faugere, M.C., Geng, Z., Paschalis, L., Qi, Q., Arnala, I., Boskey, A.L., Malluche, H.H.: Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs—effects on bone morphometry and mineral properties. *J Bone Miner Res*, 14, 1768-1778, 1999.
60. Malluche HH, Monier-Faugere MC: Understanding and managing hyperphosphatemia in patients with chronic renal disease. *Clin Nephrol* 52:267-77, 1999.
61. Pienkowski, D., Doers, T.M., Maitra, R., Monier–Faugere, M.C., Malluche, H.H.: BMD and the mechanical competence of bones in the canine skeleton. *Osteologie*, 4, 186-194, 1999.
62. Langub MC, Faugere MC, Malluche HH: Molecular bone morphometry. *Pediatr. Nephrol.* 14: 629-635, 2000.
63. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation *J Am Soc Nephrol* 11:1093-9, 2000
64. Zhao, G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausk SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. *Endocrinology* 141:2674-82, 2000.
65. Geng Z, Monier-Faugere MC, Bauss F, Malluche HH: Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. *Clin Nephrology*, 54:45-53, 2000.
66. Malluche HH, Monier-Faugere MC: Hyperphosphatemia: Pharmacologic intervention. Yesterday, today, and tomorrow. *Clin. Nephrol* 54(4):309–317, 2000.

67. Langub, M.C., Monier-Faugere, M.C., Qi, Q., Koszewski, N.J., Malluche, H.H.: Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. *J Bone Min Metab* 16: 448-456, 2001.
68. Monier-Faugere, M.C, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragment ratio in ESRD. *Kidney Int.*, 60, 1460-68, 2001.
69. Kimmel PL, Langman CB, Bogner B, Faugere M-C, Chawla LS, Watkins DW, Malluche HH: Zinc nutritional status modifies renal osteodystrophy in uremic rats. *Clin Nephro*, 56, 445-58, 2001.
70. Malluche HH, Monier-Faugere MC, Koszewski NJ. Use and indication of vitamin D analogues in patients with renal bone disease. *Nephrol Dial Transplant*, 17 Suppl 10:6-9, 2002
71. Sawaya, P, Monier-Faugere, MC, Ratanapanichkich, P, Butros, R, Wedlund PJ, Fanti, P: Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. *Clin. Nephrol*, 57, 51-55, 2002
72. Zhang M, Xuan S, Bouxsein ML, Von Stechow D, Akeno N, Faugere MC, Malluche HH, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. *J Biol Chem*. 277(46):44005-44012, 2002
73. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on Bone in Rats with Moderate Renal Failure. *Endocrinology*, 144(4):1135-1138, 2003.
74. Malluche, Mawad, H, Trueba, D, Monier-Faugere, M-C: Parathyroid hormone assays—evolution and revolutions in the care of dialysis patients. *Clin Nephrol*, 59(5):313-318), 2003.
75. Zhang M, Faugere M, Malluche H, Rosen CJ, Chernausek SV, Clemens TL: Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. *J Bone Min Res*, 18(5):836-43, 2003.
76. Coco M, Glicklich D, Faugere MC, Burris L, Bogner I, Durkin P, Tellis V, Greenstein S, Schechner R, Figueroa K, McDonough P, Wang G, Malluche H. Prevention of bone loss in renal transplant recipients: A prospective randomized trial of intravenous pamidronate. *J Am Soc Nephrol*, 14(10):2669-76, 2003.
77. Sawaya, BP, Butros, R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere, MC, Malluche H.H. Differences in bone turnover and intact PTH levels between African-American and Caucasian patients with end-stage renal disease. *Kidney Int*, 64(2):737-42, 2003.
78. Malluche H, Faugere MC: Predictive value of the PTH-(1-84)/C-PTH fragment for the assessment of bone turnover. *Kidney Int*, 2004.

79. Malluche, HH, Mawad H, Monier-Faugere, MC, The importance of bone health in end-stage renal disease: out of the frying pan into the fire? *Nephrol Dial Transplant Mar*; 19 Suppl 1:i9-13, 2004.
80. Botolin S, Faugere MC, Malluche HH, Orth M, Meyer, R, McCabe, L. R. Increased bone adiposity and PPAR γ 2 expression in Type I diabetic mice. *Endocrinology*, 146:3622-31, 2005.
81. Holmen, SL, Zylstra, CR, Mukherjee, A, Sigler, RE, Faugere, MC, Bouxsein, ML, Deng, L, Clemens, TL and Williams, BO: Essential role of beta-catenin in postnatal bone acquisition. *J Biol Chem*, 280:21162-8, 2005.
82. Lin, Y, de Villiers WJ, Garvy B, Post SR, Nagy TR, Safadi, FF, Faugere, MC, Wang, G, Malluche HH, Williams JP. The Effect of Class A Scavenger Receptor (SR-A) Deficiency in Bone. *J Bio Chem*, 282, 4653-60, 2006
83. Malluche HH, Monier-Faugere MC. Renal Osteodystrophy: What's in a Name? Presentation of a clinically useful new model to interpret bone histologic findings. *Clin Nephrol. Apr*;65(4):235-42, 2006.
84. Malluche HH, Koszewski NJ, Monier-Faugere MC, Williams JP, Mawad H. Influence of the Parathyroid Gland on Bone Metabolism. *Eur J Clin Invest Aug*; 36(2):23-33, 2006.
85. Lui, X., Bruxvoort, K., Zylstra, C., Liu, J., Cichowski, R, Faugere, M.C., Bouxsein, M., Wan, C., Williams, B. and Clemens, T. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. *Proc. Natl. Acad. Sci.*, 104, 2259-94, 2007.
86. Monier-Faugere, MC, Mawad, H, & Malluche, HH. Opposite effects of calcitriol and paricalcitol the PTH-(1-84)/large C-PTH fragments ratio in patients with chronic kidney disease stage-5. *Clin J Amer Soc Nephrol*, 2,1255-60, 2007.
87. Malluche, HH, Mawad, H, Monier-Faugere, MC: Bone biopsy in patients with osteoporosis. *Current Osteoporosis Report*, 5, 146-52, 2007.
88. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Patients with Chronic Kidney Disease Stage 5. *J Am Soc Neph*, 19, 405-412, 2008.
89. Malluche HH, Mawad H, Monier-Faugere MC: The effects of therapies of renal osteodystrophy on bone histology. *Clin J Amer Soc Nephrol*, 3, Suppl 3, S157-63, 2008.
90. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An Assessment of Cinacalcet HCl Effects on Bone Histology in Dialysis Patients with Secondary Hyperparathyroidism, *Clin. Nephrol*, 69, 269-78, 2008.

91. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. *Clin Nephrol.* 2008; 70: 284-95.
92. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Dias Curto J, Malluche HH. Low Bone Volume – A Risk Factor for Coronary Calcifications in Hemodialysis Patients. *Clin J Amer Soc Nephrol*, 4, 450-5,2009.
93. Fehmi H, Osman Y, Bhat S, Nguyen K, Daramola O, Cantor T, Monier-Faugere MC, Yee J, Malluche HH. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. *Clin Nephrol*, in press.
94. Lomashvili K, Malluche H, Monier-Faugere MC, O'Neill C. Effect of bisphosphonates on vascular calcification and bone metabolism In renal failure. *Kidney Int.*, in press.
95. Moore C, Adams E, Sudhaker Rao D, Daramola-Ogunwuyi O, Fehmi H, Bhat S, Malluche H, Monier-Faugere MC, Yee J, Osman-Malik Y. Relationship of Bone Histology to Markers of Bone and Mineral Disease in Prevalent African-American Hemodialysis Patients. Submitted to *Clin J Amer Soc Nephrol*, 2008.
96. Herberth J, Monier-Faugere MC, Mawad H, Branscum Aj, Wang G, Herberth Z, Cantor T, Malluche HH. Assessment of bone turnover by the 5 most commonly used iPTH assays, Submitted to *Kidney Int*, 2008
97. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Malluche HH. Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Submitted to *Osteoporosis Int*, 2008.

Articles submitted/ in progress

1. Horvath, G.P., Wahle, J.P., Drummond, J.F., Sammon, P.J., Matheney, C.S., Beeman, C.S., Faugere, M.C.: The effect of flurbiprofen and mechanical stress on the sagittal suture of rats in vivo. Submitted to *J Periodontal Res*.
2. Charlick DA, Walker JL, Faugere, MC, Daniels CL, Malluche HH. Alterations in bone histomorphometry in idiopathic scoliosis. *J Pediat Ortho*
3. Monier-Faugere MC, Koszewski N, Wang G and Malluche HH. PTH (7-84) Induces Increased Intact PTH Levels and Increased Number But Decreased Activity of Osteoblasts in Experimental Rats. *Am J Physiol*

Non-peer-reviewed work

1. Pellissier, J.F., Faugere, M.C., Labreque R.: Les debuts de l'insuffisance circulator cerebrale chronique. *Cahiers Sandoz Ile Rencontre franco-italienne de Geriatrie et de Geronto-psychiatrie*, 1978.
2. Pellissier, J.F., Faugere, M.C.: Les myopathies metaboliques. *Ille Journees d'Actualites Neurologiques*, 1979.

3. Pellissier, J.F., Faugere, M.C.: La Sclerose en Plaques. Etude Neuro-pathologique. Les Cahiers Medicaux Lyonnais 5:89–115, 1979.
4. Pellissier, J.F., Faugere, M.C.: Leucoencephalopathie Multifocale Progressive. Sem. Hop. Paris 56:1177–1182, 1980.
5. Faugere, M.C., Pellissier, J.F., Toga, M.: Subsequent morphological changes in periodic paralysis. A study of seven cases. Acta Neuropathol., suppl. vii:301, 1980.
6. Pellissier, J.F., Faugere, M.C., Gambarelli, D., Toga, M.: Les Paralysies Periodiques. Sem. Hop. Paris 56:1391–1401, 1980.
7. Faugere, M.C., Mussini, J.M., Pellissier, J.F., Henin, D., Gray, F., Brousse, N.: Myosites a eosinophiles et syndrome du Shulman. Sem. Hop. Paris 57:158–162,
8. Malluche, H.H. and Faugere, M.C.: Renal osteodystrophy in Mediguide to Nephrol. Vol. 1, New York, DellaCorte Publishers, 1986, pp. 1–8.
9. Malluche, H.H and Faugere, M.C.: Aluminum related bone disease. Blood Purifications 6:1–15, 1988.
10. Malluche, H.H and Faugere, M.C: Role of calcitriol in management of osteoporosis. Metabolism 33:S24–26, 1990.
11. Malluche, H.H. and Faugere, M.C: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int. 38:193–211, 1990.
12. Malluche, H.H. and Faugere, M.C: The effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int.38, Suppl. 29:S48–53, 1990.
13. Malluche HH and Faugere M–C: Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. Kidney Int. 38, Suppl. 29:S48–53, 1990.
14. Malluche, H.H., Faugere, M.C.: Role of calcitriol in the management of osteoporosis. Metabolism 33:S24–26, 1990.
15. Malluche HH, Faugere M–C, Bognar B, Friedler, RM: 1,25,26 D₃ — A novel therapeutic agent for reversal of bone loss associated with cessation of ovarian function. Proceedings: 8th Workshop on Vitamin D, Paris, 1991.
16. Malluche HH, Faugere M–C: Risk of adynamic bone disease in dialyzed patients, Kidney Int. 42 No. 4 (Suppl. 38):62–67, 1992.
17. Monier–Faugere MC, Malluche HH: Calcitriol pulse therapy in patients with end–stage renal failure. Curr Opin Nephrol Hypertens 3:615–619, 1994.

18. Malluche HH, Sawaya BP, Faugere, MC: Dialysis: current status, contemporary limitations and future challenges. *Kidney Int* 48:(Suppl. 50):S37–S39, 1995.
19. Faugere MC, Malluche HH: Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2,248 patients. *Nephrology Dialysis Transplantation* 11(Suppl 3): 111–120, 1996.
20. Langub, M.C., Koszewski, N.J., Turner, H.V., Monier–Faugere, M.C., Geng, Z., Malluche, H.H.: Bone resorption and mRNA expression of IL–6 and IL–6 receptor in patients with renal osteodystrophy. *Kidney Int.* 50(2):515–520, 1996.
21. Monier–Faugere MC, Malluche HH: Role of cytokines in renal osteodystrophy. *Curr Opinion Nephrol Hypertension* 6(4):327–332, 1997.
22. Malluche, HH, Langub M.C, Monier–Faugere MC: Pathogenesis and histology of renal osteodystrophy. *Osteoporosis Int* 7(Suppl 3):S184–S187, 1997.
23. Malluche, HH, Langub MC, Monier-Faugere MC: The role of bone biopsy in clinical practice and research. *Kidney Int* 56 Suppl 73:S20-5, 1999.
24. Malluche, HH, Mawad, H & Monier-Faugere, MC: The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? *Nephrol Dial Transplant*, 19 Suppl 1:i9-13, 2004.

Books and Book Chapters

1. Malluche, H.H. and Faugere, M.C.: *Atlas of Mineralized Bone Histology*, New York and Basel, S. Charger, 1986.
2. Malluche, H.H. and Faugere, M.C.: Bone mineral accretion and dissolution in hypercalciuric states: Pathogenesis, Consequences and Treatment edited by Coe, F.L., New York, Grune & Stratton, Inc., 1983, pp. 143–204.
3. Faugere, M.C., Abreo, K., Smith, A. and Malluche, H.H.: Bone aluminum accumulation: Etiology, prevalence and its influences on Vitamin D therapy in patients with mild to advanced renal failure *in* *Endocrine Control of Bone and Calcium Metabolism*, Elsevier Science Publishers B.V., 1985, pp. 151–152.
4. Malluche, H.H. and Faugere, M.C.: Evaluation of different biopsy techniques for qualitative and quantitative histology of bone *in* *Endocrine Control of Bone and Calcium Metabolism*, Elsevier Science Publishers B.V., 1985, pp. 351–353.
5. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P. and Friedler, R.M.: Parathyroid hormone in 1.25 Vitamin D3 exerts opposite effects on bone *in* *Phosphate and Mineral in Homeostasis* edited by Massry, S.G., Olmer, M. and Ritz, E. Plenum Publishing Corp., 1986, pp. 289–290.
6. Malluche, H.H., Faugere, M.C.: Renal bone disease *in* *Internal Medicine*, Section 4, Chapter 317, edited by Stein, J., Boston, Little Brown & Co., 1987, pp. 2118–2123.

7. Malluche, H.H., Faugere, M.C.: Therapy of aluminum related bone disease in *Clinical Disorders of Bone and Mineral Metabolism* edited by Kleerekoper, M., Krane, S.T., New York, Libart, In., Publishers, 1989, pp. 597–601.
8. Malluche, H.H. and Faugere, M.C.: The cellular basis of aluminum bone disease and its relationship to vitamin D metabolism *in* *Nephrology—Proceedings of the Xth International Congress of Nephrology*, ed. Davison, A.M., London, Balliere Tindall, W.B. Saunders, 1988, pp. 1082–1085.
9. Malluche, H.H., Faugere, M.C.: Renal bone disease *in* *Internal Medicine, Section 9, Chapter 359*, edited by Stein, J., Boston, Little Brown & Co., Third Edition, 1990, pp. 2368–2372.
10. Malluche, H.H. and Faugere, M.C.: The value of desferal infusion test for diagnosis of aluminum bone disease in patients with end stage renal failure *in* *Aluminum and Iron Overload in Hemodialysis* edited by DeBroe, M.E. Hogrefe & Huber Publishers, Toronto, Lewiston, NY, Bern, Gottingen, Stuttgart, 1989, pp. 11–15.
11. Malluche, H.H., Faugere, M.C.: Histologie der renalen Osteopathi *in* *Renale Osteopathie*, edited by Malluche, H.H., and Franz, H.E. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 1990, pp. 79–84 and 106–115.
12. Malluche, H.H. and Faugere, M.C.: Bone Biopsies: Histology and Histomorphometry of Bone *in* *Metabolic Bone Disease* edited by Avioli, L.V. and Krane, S.M., W.B. Saunders Co., 1990, pp. 283–328.
13. Malluche, H.H. and Faugere, M.C.: Renale Osteopathie *in* *Blutreinigungsverfahren*, edited by Franz, H.E., Georg Thieme Verlag, Stuttgart, 1990, pp. 277–296.
14. Malluche, H.H., Faugere, M.C., and Baker, L.R.I.: Prevention of bone disease in renal failure *in* *Prevention in Nephrology* edited by deBroe, M.E., and Verpooten G.A., Kluwer Academic Publishers, 1991, pp. 73–78.
15. Malluche, H.H. and Faugere, M.C.: Vitamin D₃ and uremic bone disease *in* *Nephrology, Vol. I* edited by Hatano, M., Springer-Verlag, Tokyo, 1991, pp. 450–454.
16. Malluche, H.H., Bognar, B., Friedler, R.M., and Faugere, M.C.: 1,25R,25(OH)₃-22 ene D₃, a novel therapeutic agent for reversal of bone loss associated with cessation of ovarian function *in* *Vitamin D—Gene Regulation Structure—Function Analysis and Clinical Application* edited by Norman, A.W., Bouillon, R., Thomasset, M., Berlin, Walter de Gruyter & Co., 1991, pp. 537–538.
17. Malluche, H.H., Faugere, M.C.: Renal bone disease *in* *Internal Medicine, Section 9, Chapter 186, 4th Edition*, edited by Stein, J., Boston, Little Brown & Co., 1993, pp. 2802–2811.
18. Malluche, H.H., Faugere, M.C.: Mechanisms of bone loss after cessation of ovarian function—therapeutic implications (Übersichtsreferat) *in* *Osteologie akutel VII*, edited by Pesch, H.J., Stoss, H., Kummer, B., Springer-Verlag, Berlin, 1993, pp. 405–409.

19. Kurz, P., Faugere, M.C., Roth, P., Werner, E., Vlachoianis, J., Malluche, H.H., Grutzmacher, P.: Differenzierung der renalen Osteopathi mit Hilfe kalziumkinetischer Parameter in Osteologie akutel edited by Pesch, H.J., Stoss, H., Kummer, B., Springer-Verlag, Berlin, 1993, pp. 488–491.
20. Malluche, H.H., Faugere, M.C.: Renal bone disease in Internal Medicine, Section 9, Chapter 186, 5th Edition, edited by Stein, J., Boston, Little Brown & Co., 1997, Fifth Edition, pp.1961–1965.
21. Malluche, H.H., Faugere, M.C: Bone biopsies: a modern approach in Metabolic Bone Disease edited by Avioli, L.V., and Krane, S.M., W.B. Saunders Co., 1997, Third Edition, pp. 237–273.
22. Monier-Faugere, M.C., Malluche, H.H.: Mineralized bone histology in the normal and uremic state in Renal Osteodystrophy, edited by Bushinsky, D.A., Philadelphia, Lippincott-Raven, 1998, pp. 49–87.
23. Monier-Faugere, M.C., Malluche, H.H.: Renal osteodystrophy in Cecil Textbook of Medicine, edited by Goldman L, Bennett JC, Philadelphia, W.B. Saunders, 2000.
24. Monier-Faugere, M.C., Sawaya, B.P., Malluche, H.H.: Renal osteodystrophy in Clinical Nephrology, Dialysis and Transplantation, edited by Feistle, K., Munich, Dusti-Verlag, 2000.
25. Monier-Faugere, M.C., Langub, M.C., Malluche, H.H.: Bone biopsy in patients with renal failure in Textbook of Nephrology, edited by Massry, S.G., Glasscock, R.J., Baltimore, Williams and Wilkins, 2001.
26. Monier-Faugere, M.C., Sawaya B.P., Langub, M.C., Malluche, H.H: Bone –Normal Structure an Physiology in: Calcium in Internal Medicine, edited by Morii, H, Nishizawana, Y, and Massry, S.G., Springer, London, Berlin, 2002.
27. Monier-Faugere, M.C., Malluche, H.H.: Renal osteodystrophy in Cecil Textbook of Medicine, 22nd ed., edited by Goldman L, Bennett JC, Philadelphia, W.B. Saunders, 2003.
28. Monier-Faugere MC, Malluche HH: Histologic Abnormalities of Bone Before and After Kidney Transplantation. In Bone Disease of Organ Transplantation, edited by Shane E and Compston J, San Diego, Elsevier Inc. 2005.

Monographs

1. Faugere, M.C.: Les Paralysies Periodiques. Memoire de C.E.S. d'anatomie pathologic, 1976.
2. Faugere, M.C.: Innervation motrice terminale dans les myopathies steroidiennes. Memoire de Medaille Dr. des Hopitaux de Marseille, 1976.
3. Faugere, M.C.: Les myopathies centronucleaires. Thesis, Marseille, France, 1978.
4. Faugere, M.C.: Atteintes musculaires de l'osteomalacie. Etude experimentale. Memoire de D.E.A. de Neuropathologie, 1979.

Editorials

1. Malluche, H.H. and Faugere, M.C.: Renal osteodystrophy. *New Engl J Med* 321:317–319, 1989.
2. Malluche, H.H. and Faugere, M.C.: Renal bone disease 1990: An unmet challenge for the nephrologist. *Kidney Int.* 38:193–211, 1990.
3. Malluche, H.H. and Faugere, M.C.: Uremic bone disease: Current knowledge, controversial issues and new horizons. *Min. Elec. Metab.* 17:281–296, 1991.

Letters to the editor

1. Malluche, H.H. and Faugere, M.C.: Letter to the editor. *New Engl J Med* 321: 1833, 1989.
2. Malluche, HH & Monier-Faugere, MC: PTH 1-84, PTH fragments and bone turnover. *Am J Kidney Dis*, 41:1127, 2003.

Abstracts

1. Faugere, M.C., Malluche, H.H., Okamoto, S. and DeLuca, H.F.: Protective effect of 1,25(OH)₂ Vitamin D against bone loss in oophorectomized rats. *Clin. Res.* 30:741A, 1982.
2. Malluche, H.H., Faugere, M.C., Fanti, P. and Price, P.A.: Serum levels of bone Gla protein predict underlying bone histology in dialyzed patients. *Kidney Int.* 23:105, 1982.
3. Abreo, K., Faugere, M.C., Smith, A., Yokel, R., Julian, B.A., Kluge, R., Friedler, R.M. and Malluche, H.H.: Prevalence and etiology of aluminum intoxication in non-dialyzed and dialyzed patients with renal failure. *Kidney Int.* 23:141, 1982.
4. Faugere, M.C. and Malluche, H.H.: Does bone aluminum intoxication cause resistance to vitamin D therapy? *Kidney Int.* 23:99, 1982.
5. Malluche, H.H., Faugere, M.C. and Dorr, L.D.: Systemic changes in bone structure and bone formation in patients with osteoarthritis. *Orthopedic Trans.* 7:299–300, 1983.
6. Faugere, M.C., Dorr, L.D. and Malluche, H.H.: Static and dynamic bone histology in primary and revision total knee arthroplasty. *Orthopedic Trans.* 7:299–300, 1983.
7. Faugere, M.C., Malluche, H.H., Okamoto, S. and Delco, H.F.: 1,25(OH)₂D₃ reverses bone loss due to oophorectomy. *Calcif. Tissue Int. Supp.* 35:A10, 1983.
8. Malluche, H.H., Faugere, M.C., Fanti, P. and Price, P.A.: Bone Gla-protein—A biochemical index of bone formation and mineralization in uremic patients. *Calcif. Tissue Int. Suppl.* 35:38A, 1983.

9. Malluche, H.H., Faugere, M.C., Fanti, P. and Price, P.A.: Bone Gla—protein—A marker for osteoblastic activity. *Clin. Res.* 31:391A, 1983.
10. Faugere, M.C., Malluche, H.H., Okamoto, S., Deluca, H.F.: Protective effect of 1,25(OH)₂ Vitamin D against bone loss in oophorectomized rats. *Clin. Res.* 31:385A, 1983.
11. Malluche, H.H., Faugere, M.C., Abreo, K., Smith, A. and Friedler, R.M.: Bone aluminum intoxication in renal failure—etiology, prevalence and effects on Vitamin D therapy. *Clin. Res.* 31:435A, 1983.
12. Malluche, H.H., Faugere, M.C., Fanti, P. and Price, P.A.: Serum levels of bone Gla—protein reflect bone formation and mineralization in dialyzed patients. *Calcif. Tissue Int.* 35:757A, 1983.
13. Malluche, H.H., Faugere, M.C., Abreo, K., Smith, A. and Friedler, R.M.: Aluminum intoxication of bone—etiology and prevalence in renal patients on or before dialysis. *Calcif. Tissue Int.* 35: 672A, 1983.
14. Faugere, M.C. and Malluche, H.H.: Optimal size of bone samples for quantitative and qualitative histology. *Calcif. Tissue Int.* 35:669A, 1983.
15. Faugere, M.C. and Malluche, H.H.: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Clin. Res.* 31:738A, 1983.
16. Malluche, H.H., Smith, A.J., Abreo, K. and Faugere, M.C.: Reversal of bone aluminum accumulation (BAA) in dialyzed patients treated with desferrioxamine (DFO). *Clin. Res.* 31:750A, 1983.
17. Smith, A.J., Faugere, M.C., Abreo, K. and Malluche, H.H.: Single desferrioxamine (DFO) infusion (DFO Test) for diagnosis of bone aluminum accumulation of (BAA) in patients with renal failure. *Clin. Res.* 31:751A, 1983.
18. Faugere, M.C., Ritz, E. and Malluche, H.H.: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Kidney Int.* 25:142, 1984.
19. Faugere, M.C. and Malluche, H.H.: Endogenous calcitonin is not a long—term modulator of effects of parathyroid hormone on bone. *Physiologist* 27:253, 1984.
20. Malluche, H.H., Okamoto, S., Deluca, H.F. and Faugere, M.C.: Bone loss of estrogen deficiency results from osteoblastic dysfunction—a defect reversed by 1,25(OH)₂ Vit D₃. *Physiologist* 27:253, 1984.
21. Smith, A.J., Faugere, M.C., Abreo, K. and Malluche, H.H.: The value of single desferrioxamine infusion (DFO Test) for diagnosis of organ aluminum accumulation. *Clin. Res.* 32:408A, 1984.
22. Faugere, M.C., Caillens, G., Ritz, E. and Malluche, H.H.: Is there a protective effect of endogenous calcitonin against secondary hyperparathyroidism? *Calcif. Tissue Int.* 36:476, 1984.
23. Smith, A.J., Faugere, M.C., Abreo, K. and Malluche, H.H.: The value of single desferrioxamine (DFO) infusion for diagnosis of bone aluminum accumulation (BAA). *Kidney Int.* 25: 154, 1984.

24. Malluche, H.H., Smith, A.J., Abreo, K. and Faugere, M.C.: Successful removal of aluminum from bone of dialyzed patients treated with desferrioxamine (DFO). *Kidney Int.* 25: 188, 1984.
25. Faugere, M.C. and Malluche, H.H.: Does endogenous calcitonin (CT) protect against osteitis fibrosa (OF) in renal failure? *Clin. Res.* 32:394A, 1984.
26. Faugere, M.C., Reitz, R., Endress, B.P. and Malluche, H.H.: Serum parathyroid hormone levels reflect preferentially osteoblastic activity in patients with renal failure. *Clin. Res.* 32: 763A, 1984.
27. Fanti, P., Faugere, M.C., Price, P.A. and Malluche, H.H.: Plasma levels of bone Gla-protein reflect bone formation and not mineralization or resorption in patients on chronic maintenance dialysis. *Clin. Res.* 32:769A, 1984.
28. Malluche, H.H., Abreo, K. and Faugere, M.C.: Accumulation of aluminum in bone is associated with decreased mineralization and turnover—an effect dependent on the localization of aluminum in bone. *Clin. Res.* 32:802A, 1984.
29. Malluche, H.H., Smith, A.J., Abreo, K. and Faugere, M.C.: Reversal of bone aluminum accumulation (BAA) in dialyzed patients treated with desferrioxamine (DFO). *Clin. Res.* 32:453A, 1984.
30. Malluche, H.H., Abreo, K. and Faugere, M.C.: Aluminum decreases turnover and mineralization of bone—an effect dependent on its localization in bone. *Calcif. Tissue Int.* 36:494, 1985.
31. Malluche, H.H., Reitz, R., Endres, D. and Faugere, M.C.: In vivo evidence that parathyroid hormone stimulates preferentially osteoblasts rather than osteoclasts. *Calcif. Tissue Int.* 37:477, 1985.
32. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P. and Friedler, R.M.: 1,25(OH)₂D₃ regulates activity of bone cells and PTH modulates number of bone cells. *Min. Electrol. Metab.* 11:330–331, 1985.
33. Faugere, M.C., Abreo, K. and Malluche, H.H.: Localization of aluminum in bone determines the pathologic effects associated with accumulation of aluminum in bone in hemodialyzed patients. *Kidney Int.* 27:114, 1985.
34. Malluche, H.H., Reitz, R., Endres, D. and Faugere, M.C.: Serum parathyroid hormone levels predict preferentially osteoblastic activity in patients with renal failure. *Kidney Int.* 27: 122, 1985.
35. Friedler, R.M., Faugere, M.C. and Malluche, H.H.: Aluminum causes not only osteomalacia but also osteopenia in hemodialyzed patients. *Kidney Int.* 27:161, 1985.
36. Faugere, M.C., Bradac, C.J. and Malluche, H.H.: Bone pathology resulting from bone aluminum accumulation depends upon localization of aluminum in bone. *Clin. Res.* 33:492A 1985.
37. Freundlich, M., Faugere, M.C., Zilleruelo, G., Strauss, J. and Malluche, H.H.: Aluminum accumulation in brain with normal aluminum content in bone resulting from formula feeding of uremic infants. *Clin. Res.* 33:483A, 1985.

38. Freundlich, M., Faugere, M.C., Zilleruelo, G., Abitbol, C., Bradac, C.J., Strauss, J. and Malluche, H.H.: Milk formula causes aluminum toxicity in uremic infants. Soc. Ped. Res. 19:376A, 1985.
39. Faugere, M.C., Rush, M., Friedler, R.M. and Malluche, H.H.: Loss of ovarian function causes bone loss due to an osteoblastic insufficiency in dogs. Clin. Res. 33:849A, 1985.
40. Malluche, H.H., Faugere, M.C., Friedler, R.M. and Fanti, P.: 1,25(OH)₂D₃ increases activity of bone cells in vivo—an effect contrary to the action of PTH on bone. Sixth Int. Workshop on Vitamin D, Milan, Italy, 1985.
41. Faugere, M.C., Smith, A.J. and Malluche, H.H.: Aluminum accumulation in bone causes bone loss in uremic patients. Clin. Res. 33:429A, 1985.
42. Malluche, H.H., Reitz, R., Endres, D. and Faugere, M.C.: In vivo evidence that parathyroid hormone stimulates preferentially osteoblasts rather than osteoclasts. J. Bone Min. Res. 1:134, 1986.
43. Cooper, K., Lang, R., Ellison, A., Hendler, E., Faugere, M.C. and Malluche, H.H.: Aluminum related bone disease: high prevalence despite low dialysate aluminum. J. Bone Min. Res. 1:92, 1986.
44. Faugere, M.C., Matthews, C., Friedler, R.M. and Malluche, H.H.: Effects of parathyroid hormone and 1,25(OH)₂D₃ on accumulation of aluminum in bone in dogs with renal failure. EDTA, Budapest, Hungary, 1986.
45. Faugere, M.C., Arnala, I.O., Ritz, E. and Malluche, H.H.: Aluminum causes not only osteomalacia but also osteopenia in hemodialyzed patients. EDTA, Budapest, 1986.
46. Faugere, M.C., Rush, M., Friedler, R.M. and Malluche, H.H.: Loss of ovarian function causes bone loss due to an osteoblastic insufficiency in dogs. Clin. Res 34:544A, 1986.
47. Faugere, M.C., Matthews, C., Friedler, R.M. and Malluche, H.H.: Effects of parathyroid hormone and 1,25(OH)₂D₃ on accumulation of aluminum in bone in dogs with renal failure. Kidney Int. 29:213, 1986.
48. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P. and Friedler, R.M.: 1,25(OH)₂ Vit D₃ maintains activity of bone cells and PTH modulates number of bone cells in dogs with moderate renal failure. Kidney Int. 29:165, 1986.
49. Faugere, M.C., Friedler, R.M., Rush, M. and Malluche, H.H.: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. Int. Conf. on Calcium Regulating Hormones, Nice, France, 1986.
50. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P. and Friedler, R.M.: 1,25(OH)₂ Vit D₃ maintains activity of bone cells and parathyroid hormone modulates number of bone cells in dogs with renal failure. Int. Conf. on Calcium Regulating Hormones, Nice, France, 1986.
51. Fanti, P., Faugere, M.C., Smith, A.J. and Malluche, H.H.: Removal of aluminum (Al) is associated with increased production of 1,25(OH)₂ Vit D₃ in dialysis patients. Kidney Int. 31:346, 1987.

52. Smith, A.J., Faugere, M.C., Fanti, P. and Malluche, H.H.: Trade in and trade off of deferoxamine (DFO) in therapy in hemodialyzed patients. *Kidney Int.* 31:246, 1987.
52. Malluche, H.H., Fanti, P., Friedler, R.M. and Faugere, M.C.: Decreased activity of bone cells contributes to the pathogenesis of early renal osteodystrophy—an abnormality reversed by 1,25(OH)₂D. *Kidney Int.* 31:353, 1987.
53. Malluche, H.H., Matthews, C., Faugere, M.C., Fanti, P., Endres, D.B. and Friedler, R.M.: 1,25(OH)₂D maintains bone cell activity and parathyroid hormone modulates bone cell number in experimental dogs. *Transactions of the 33rd Annual Meeting, Orthopaedic Research Society, Vol. 12:286, 1987.*
54. Faugere, M.C., Friedler, R.M. and Malluche, H.H.: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function. *Transactions of the 33rd Annual Meeting, Orthopaedic Research Society, Vol. 12:354, 1987.*
55. Malluche, H.H., Faugere, M.C. and Friedler, R.M.: An osteoblastic defect is responsible for maintenance of bone loss after ovariectomy in dogs. *Bone, Structure, Function and Disease Symposium, Australia, 1987.*
56. Malluche, H.H., Faugere, M.C., Friedler, R.M. and Fanti, P.: 1,25(OH)₂D reverses bone loss but suppresses bone remodeling in beagle dogs with cessation of ovarian function. *Bone, Structure, Function and Disease Symposium, Australia, 1987.*
57. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: 1,25(OH)₂D₃ reverses bone loss associated with cessation of ovarian function in experimental dogs. *Clin. Res.* 35, No. 3:502A, 1987.
58. Fanti, P., Faugere, M.C., Smith, A.J. and Malluche, H.H.: Aluminum removal in dialysis patients results in higher circulating levels of 1,25(OH)₂ Vit D. *Clin. Res.* 35, No. 3:546A, 1987.
59. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: The effects of 1,25(OH)₂ Vit D₃ on bone loss associated with cessation of ovarian function in experimental dogs. *J. Bone Min. Res.* 2:476, 1987.
60. Fanti, P., Faugere, M.C., Smith, A.J. and Malluche, H.H.: Removal of aluminum is associated with increased production of 1,25 Vit D in patients with end stage renal failure. *J. Bone Min. Res.* 2:452, 1987.
61. Smith, A.J., Malluche, H.H., Faugere, M.C. and Fanti, P.: Trade in and trade off of deferoxamine (DFO) therapy in hemodialyzed patients. *Xth Int. Cong. of Nephrology, London:175, 1987.*
62. Fanti, P., Faugere, M.C., Smith, A.J. and Malluche, H.H.: Increase blood levels of 1,25 Vit D after aluminum removal in hemodialyzed patients. *Xth Int. Cong. of Nephrology, London:423, 1987.*
63. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: The effects of 1,25(OH)₂D₃ on bone loss associated with cessation of ovarian function in experimental dogs. *International Symposium on Osteoporosis, Denmark, Abstract 302, 1987.*
64. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: The effects of

- 1,25(OH)₂D₃ on bone loss associated with cessation of ovarian function in experimental dogs. XX European Symposium on Calcified Tissues, Sirmione, Italy, 1987.
65. Malluche, H.H., Faugere, M.C. and Friedler, R.M.: The osteoblastic defect is responsible for maintenance of bone loss after ovariectomy in dogs. XX European Symposium on Calcified Tissues, Sirmione, Italy, 1987.
 66. Fanti, P., Faugere, M.C., Smith, A. and Malluche, H.H.: Increased blood levels of 1,25 Vit D after aluminum removal in hemodialyzed patients. XXIVthe Congress of the European Dialysis and Transplantation Association, Berlin, 1987.
 67. Malluche, H.H., Faugere, M.C., Friedler, R.M. and Fanti, P.: Can 1.25 Vit D reverse the bone loss associated with cessation of ovarian function. Transactions of the 34th Annual Meeting Orthopaedic Research Society, Volume 13:479, 1988.
 68. Dorr, L.D., Faugere, M.C., Bognar, B., Mackel, A.M. and Malluche, H.H.: Histologic validation of a new X-ray classification of hip changes in patients with osteoarthritis requiring total hip replacement. Transactions of the 34th Annual meeting Orthopaedic Research Society, Volume 13:349, 1988.
 69. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y. and Malluche, H.H.: 1,25 D₃ administration in moderate renal failure. Clin. Res. 36, No. 3:592A, 1988.
 70. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y. and Malluche, H.H.: 1,25 D₃ administration in moderate renal failure. 7th Workshop on Vitamin D, Rancho Mirage, CA, 1988.
 71. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: Lack of histologic signs of Vit D deficiency in early development of renal osteodystrophy. Journal of Bone and Mineral Research 3, Supplement I: S95, 1988.
 72. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y. and Malluche, H.H.: Bone histomorphometric changes after 1,25 D₃ administration in moderate renal failure. The Fifth International Congress on Bone Morphometry, Niigata, Japan, p. 71, 1988.
 73. Faugere, M.C., Friedler, R.M., Fanti, P. and Malluche, H.H.: Lack of histologic signs of Vit D deficiency in the early development of renal osteodystrophy. The Fifth International Congress on Bone Morphometry, Niigata, Japan, p. 118, 1988.
 74. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y. and Malluche, H.H.: Bone histomorphometric changes after 1,25 D₃ administration in moderate renal failure. Fifth International Congress on Nutrition and Metabolism in Renal Disease, Strasbourg, France, 1988.
 75. Malluche, H.H. and Faugere, M.C.: Diagnosis of Aluminum Bone Disease. XXVth Congress of the European Dialysis and Transplant Association, Madrid, Spain, 1988.
 76. Baker, L.R.I., Abrams, S.M.L., Roe, C.J., Faugere, M.C., Fanti, P., Subayti, Y. and Malluche, H.H.: Use of 1,25D₃ in patients with moderate renal failure. Kidney Int. 35:220, 1988.

77. Faugere, M.C., Friedler, R.M., Fanti, P., Malluche, H.H.: Lack of histologic signs of Vit D deficiency in the early development of renal osteodystrophy. *Kidney Int.* 35:377, 1988.
78. Malluche, H.H., Dorr, L.R., Bogнар, B., Faugere, M.C.: Osteopenia in 97 patients with osteoarthritis. Orthopedic Research Society, Feb., 1989.
79. Faugere, M.C., Friedler, R.M., Fanti, P., Malluche, H.H.: Incipient histological and biochemical derangements of renal osteodystrophy. *Clin. Res.* 37, No. 2:570A, 1989.
80. Malluche, H.H., Faugere, M.C., Fanti, P., Abrams, S.M.L., Baker, L.R.I.: Calcitriol administration in moderate renal failure. *Calcium '89: 2nd International Symposium on Preventive and Therapeutic Use of Calcium, Vitamin D and Other Calcitropic Drugs*, Prague, Czechoslovakia, 1989.
81. Malluche, H.H., Faugere, M.C., Friedler, R.M., Fanti, P.: Development of bone loss after cessation of ovarian function and its reversal with 1,25(OH)2D3. *Steenbock Symposium on Osteoporosis*, University of Wisconsin–Madison, 1989.
82. Faugere, M.C., Friedler, R.M., Fanti, P., Malluche, H.H.: Induction and maintenance of bone loss after cessation of ovarian function. *American Society of Bone and Mineral Research Annual Meeting*, September, 1989.
83. Malluche, H.H., Slatopolsky, E., Faugere, M.C.: The deferoxamine infusion test (DFO test): a multi center study. *Kidney Int.* 37:309, 1990.
83. Malluche, H.H., Slatopolsky, E., Faugere, M.C.: Can aluminum bone disease be diagnosed by noninvasive tests? *International Congress of Nephrology meeting*, Tokyo, Japan, July, 1990.
84. Kimmel, P., Bogнар, B., Watkins, D., Faugere, M.C., Langman, C., Malluche, H.H.: Zinc depletion and renal osteodystrophy in the rat. *23rd Annual Meeting, American Society of Nephrology*, December, 1990.
85. Dorr, L.D., Gruen, T.A.W., Faugere, M.C., Malluche, H.H.: Influence of bone on failure of THR. *18th World Congress of the Societe Internationale de Chirurgie Orthopedique et de Traumatologie*, Montreal, 1990.
86. Kurz, P., Bogнар, B., Roth, P., Werner, E., Vlachoјannis, J., Grutzmacher, P., Faugere, M.C., Malluche, H.H.: Relationship between bone turnover and plasma calcium clearance (CACL) in patients with uremic bone disease. *Renal Bone Disease, PTH and Vitamin D Symposium*, 1990.
87. Kurz, P., Bogнар, B., Roth, P., Werner, E., Faugere, M.C., Malluche, H.H., Vlachoјannis, J., Grutzmacher, P.: Beziehung zwischen Knochen turnover und der Plasmacalciumclearance in Patienten mit Uramischer Osteodystrophie. *21 Kongres der Gesellschaft fur Nephrology*, Badgastein, September 1990.
88. Faugere, M.C., Friedler, R.M., Fanti, P., Malluche, H.H.: Elevation of parathyroid hormone in incipient renal failure: a compensatory mechanism to offset decreased 1,25 Vit D levels. *J. Bone Min. Res.* 5:S238, 1990.
89. Malluche, H.H., Friedler, R.M., Fanti, P., Faugere, M.C.: Elevated PTH levels are needed for normal serum 1,25D in incipient renal failure. *23rd Annual Meeting*,

- American Society of Nephrology, December, 1990.
90. Malluche, H.H., Faugere, M.C., Bognar, B., Friedler, R.F.: 1,25,26 D₃—A novel therapeutic agent for reversal of bone loss associated with cessation of ovarian function. 8th Workshop on Vitamin D, Paris, 1991.
 91. Malluche HH, Friedler RM, Fanti P, Faugere M—C: Secondary hyperparathyroidism—A low compensatory phenomenon to overcome low 1,25Vit D levels in incipient renal failure. *Calc Tiss.* 48:A86, 1991.
 92. Bognar B, Faugere M—C, Malluche HH: Cyclic administration of 1,25(OH)₂D₂ and 1,25(OH)₂–24EPI–D₂ prevents bone loss in ovariectomized rats. *J Bone & Min. Res.* 6:S239, 1991.
 93. Faugere M—C, Bognar B, Friedler RM and Malluche HH: 1,25R,26(OH)₃–22 ene D₃ (RO 23–8525) reverses bone loss associated with cessation of ovarian function without suppression of bone turnover in experimental dogs. *J Bone Min. Res.* 6: S216, 1991.
 94. Juvin, R, Allen, SH, Faugere M—C and Malluche HH: Serum tartrate–resistant acid phosphatase reflects histomorphometric parameters of osteoclasts in dialyzed patients. *J Bone Min. Res.* 6:S152, 1991
 95. Malluche HH, Juvin R, Allen SH and Faugere M—C: Serum tartrate–resistant acid phosphatase reflects osteoclastic resorption better than PTH in dialyzed patients. *JASN.* 2:337, 1991.
 96. Malluche HH, Juvin R, Allen SH and Faugere M—C: Magnesium administration prevents the thiazide–induced increase in osteocyte number in normal dogs. *JASN* 2:620, 1991.
 97. Metsger DS, Arnala I, Faugere M—C and Malluche HH: Histomorphometric analysis of tricalcium phosphate ceramic implanted into turkeys. *Proceedings: Fourth World Biomaterials Congress, Berlin, Germany, 1992.*
 98. Arnala I, Tarvainen R, Nevalainen T., Alhava E, Faugere M—C, Malluche HH: Clodronate does not affect bone resorption or bone turnover in dietary–induced hyperparathyroidism in beagle dogs. *J Bone and Min. Res.*, 7(Suppl. 1):289, 1992.
 99. Monier–Faugere M—C, Friedler RM, Bauss F, Malluche HH: A new bisphosphonate, BM21.0955, prevents bone loss occurring after cessation of ovarian function in experimental dogs. *J Bone and Min. Res.*7(Suppl. 1):277, 1992.
 100. Kimmel L, Bognar B, Watkins D, Faugere M—C, Langman C, Malluche HH: Zinc depletion limits hyperparathyroid renal osteodystrophy in rats. *JASN* 3:674, 1992.
 101. Faugere, M.C., Bauss, F., Friedler, R.M., Malluche, H.H.: Preventive effects of the new bisphosphonate, BM 21.0955, on the bone loss occurring after cessation of ovarian function in experimental dogs. *Bone* 13(5):A10, 1992.
 102. Horvath, G.P., Wahle, J.P., Drummond, J.F., Sammon, P.J., Matheney, C.S., Beeman, C.S., Faugere, M.C.: The effect of fluriprofen and mechanical stress on the sagittal suture of rats in vivo. *Bone* 13(5):A14, 1992.

103. Juvin, R., Faugere, M.C., Malluche, H.H.: Comparison between different methods of measurement of bone resorption. *Bone* (13(5):A17, 1992.
104. Kurz, P., Faugere, M.C., Roth, P., Werner, E., Vlachojannis, J., Grützmacher, Malluche, H.H.: Calcium kinetics studies in patients with renal osteodystrophy. *Bone* 13(5):A19, 1992.
105. Metsger, D.S., Arnala, I., Faugere, M.C., Malluche, H.H.: Histomorphometric analysis of tricalcium phosphate implanted into turkeys. *Bone* 13(5):A23, 1992.
106. Dorr, L.D., Mackel, A.M., Faugere, M.C., Gruen, T.A., Malluche, H.H.: Structural and cellular characteristics of proximal femoral bone in patients for total hip replacement. *Bone* 13(5):A9, 1992.
107. Costa M, Faugere M–C, Malluche HH: Persistence of aluminum bone disease despite substitution of aluminum containing phosphate binders by calcium salts in patients on chronic dialysis. *JASN* 4:694, 1993.
108. Faugere M–C, Friedler, RM, Malluche HH: Efficacy and limitations of pulse I.V and pulse oral 1,25 Vit D therapy on bone disease in patients on chronic dialysis. *JASN* 4:695, 1993.
109. Kurz P, Tsobanelis T, Roth P, Werner E, Faugere M–C, Schoeppe W., Vlachojannis J, Malluche HH: Calcium turnover is lower in patients on continuous ambulatory peritoneal dialysis (CAPD) than in hemodialyzed patients (HD) despite similar PTH levels. *J. Amer. Soc. Nephrol* 4: 410, 1993.
110. Malluche HH, Faugere M–C, Hruska K, Salusky I, Sawaya P: Bone biopsies in patients with renal failure: Why, When and How. Short course. *J. Amer. Soc. Nephrol* 4:11, 1993.
111. Lapuz MH, Koszewski NJ, Faugere MC, Jueppner H, Malluche HH: Demonstration of human parathyroid hormone receptor messenger ribonucleic acid in osteoblasts, lining cells and osteocytes of plastic–embedded bone biopsy specimens from uremic patients. *J. Bone Miner. Res.* 9:S232, 1994.
112. Geng ZP, Faugere MC, Qi QL, Malluche HH: Predictive value of serum osteocalcin for bone turnover in patients with osteoporosis. *J. Bone Miner. Res.*9:S402, 1994.
113. Doers T, Pienkowski D, Faugere MC, Malluche HH. Calcitonin reduces bone mineral density and torsional mechanical properties of canine tibiae. *J. Bone Miner. Res.* 9:S268, 1994.
114. Qi QL, Faugere MC, Geng AP, Malluche HH: Sensitivity and specificity of serum levels of intact parathyroid hormone in predicting bone turnover in renal osteodystrophy. *J. Bone Min. Res.* 9:S228, 1994.
115. Kurz P, Monier–Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Calcium kinetics studies in patients with renal osteodystrophy. Proceedings, 31st Congress of the EDTA European Renal Association, Vienna, Austria, 1994.
116. Briner V, Thiel G., Faugere MC, Landsmann J, Malluche HH. Prevention of osteopenia but persistence of renal bone disease after kidney transplantation. *JASN*

- 5(3): 996, 1994.
117. Faugere MC, Qi QL, Geng ZP, Malluche HH. What serum levels of parathyroid hormone discriminate between high vs. normal or low bone turnover in dialyzed patients? *JASN* 5(3):878, 1994.
 118. Sawaya B, Qi QL, Faugere MC, Malluche HH. High bone turnover (HBT) without increase in serum parathyroid hormone (PTH) in rats with mild chronic renal failure (MCRF). *JASN* 5(3):888, 1994.
 119. Walker J, Faugere MC, Arnala I, Malluche HH. Bone histomorphometry in children with myelomenigocele and cerebral palsy—preliminary results. *Dev. Med. Child Neurol* 36(9) Suppl 70; 3, 1994.
 120. Malluche, H.H., Monier–Faugere, M.C.: The changing spectrum of renal bone disease over the last decade. *EDTA*, 1994.
 121. Doers, T., Pienkowski, D., Faugere, M.C., Malluche, H.H.: Calcitonin reduces bone mineral density and load bearing mechanical properties of canine bones. *Trans. Orthop. Res. Soc.* 20:156, 1995.
 122. Sawaya, B.P., Koszewski, N., Fanti, P, Qi, Q., Faugere M.C., Malluche, H.H.: Evidence for abnormal binding of vitamin D–receptor complex to vitamin D response elements (VDRE) in rats with incipient renal failure. *JASN* 6(3):970, 1995.
 123. Faugere, M.C., Geng, Z., Qi, Q., Malluche, H.H.: Serum levels of insulin–like growth factor–1 and its binding protein–3 do not reflect bone formation in patients on chronic maintenance dialysis. *JASN* 6(3):935, 1995.
 124. Faugere, M.C., Geng, Z., Qi, Q., Malluche, H.H.: Effects of calcitonin on bone loss after cessation of ovarian function in beagle dogs—evidence for an osteoblastic insufficiency. *Trans Orthop Res Soc*, 1995.
 125. Qi, Q., Faugere, M.–C., Geng, Z., Malluche, H.H.: Calcitonin prevents the early bone loss after cessation of ovarian function but induces osteoblastic insufficiency in beagle dogs. *J Bone Miner Res* 10(Suppl 1):S354, 1995.
 126. Geng, Z., Faugere, M.–C., Qi, Q., Bauss, F., Malluche, H.H.: Ibandronate reverses bone loss after cessation of ovarian function in beagle dogs. *J Bone Miner Res* 10(Suppl 1):S199, 1995.
 127. Faugere, M.–C., Briner, V., Thiel, G., Malluche, H.H.: Prevention of osteopenia but persistence of renal bone disease two years after kidney transplantation. *J. Bone Miner. Res.* 10(Suppl 1):S512, 1995.
 128. McCarter J, Pienkowski D, Faugere M–C, Malluche HH, Kryscio R: Compatibility of bone mineral densities and mechanical properties of vertebrae and long bones in a canine model. *Trans Orthop Res Soc*, 1996.
 129. Geng Z, Faugere M–C, Qi Q, Slatopolsky E, Friedler RM, Kubodera N, Malluche HH: 22–Oxacalcitriol suppresses parathyroid hormone secretion and preserves bone turnover in dogs with renal failure. *J Bone Miner Res* 11(Suppl 1):S490, 1996.

130. Qi, Q, Faugere M–C, Geng Z, Devane J, Malluche HH: 24–epi–1 α ,25–dihydroxyvitamin D₂ reverses bone loss after cessation of ovarian function without inducing low bone turnover in beagle dogs. *J Bone Miner Res* 11(Suppl 1):S225, 1996.
131. Langub MC Jr, Koszewski NJ, Faugere M–C, Geng Z, Malluche HH: Intensity of mRNA expression for interleukin–6 receptor in osteoclasts parallels bone resorption in patients with renal osteodystrophy. *J Bone Miner Res* 11(Suppl 1):S491, 1996.
132. Sawaya BP, Koszewski NJ, Qi Q, Langub MC, Faugere M–C, Malluche HH: Defective vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure. Presented at the Am Soc Bone Miner Res annual meeting, 1996.
133. Fanti P, Faugere MC, Geng Z, Schmidt J, Cohen D, Malluche HH: Systemic administration of genistein partially prevents bone loss in ovariectomized rats via a nonestrogen–like mechanism. Submitted to the Second International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, Brussels, Belgium, September 1996.
134. Faugere MC, Geng Z, Qi Q, Slatopolsky E, Friedler RM, Kubodera N, Malluche HH: Prevention of secondary hyperparathyroidism without suppression of bone turnover in dogs with renal insufficiency treated with 22–Oxacalcitriol. *J Am Soc Nephrol* 7(9):1790, 1996.
135. Vasconez HC, Rodgers JB, Fink BF, Deluca P, Faugere MC, Malluche HH: A novel delivery vehicle for growth factors in cranial bone surgery, a rabbit study. Poster presentation, 41st Annual Meeting, Plastic Surgery Research Council, St. Louis, MO, June 1996.
136. Faugere, M.C., Qi, Q., Geng, Z., Devane, J., Malluche, H.H.: Correction of bone loss with estrogen deficiency by 24–epi–1 α ,25–dihydroxyvitamin D₂. *Bone* 19(3, Suppl):140S, 1996.
137. Langub, M.C. Jr., Koszewski, N.J., Faugere, M.C., Geng, Z., Malluche, H.H.: Erosion depth is paralleled by expression of mRNA for interleukin–6 receptor in osteoclasts. *Bone* 19(3, Suppl):148S, 1996.
138. Geng, Z., Faugere, M.C., Qi, Q., Slatopolsky, E., Friedler, R.M., Kubodera, N., Malluche, H.H.: Suppression of PTH secretion without concomitant decrease in bone turnover in renal failure. *Bone* 19(3, Suppl):141S, 1996.
139. Vasconez, H., Rodgers, J., Fink, B., Duggirala, S., Deluca, P., Faugere, M., Malluche, H.H.: Rabbit study of novel delivery vehicles for rhBMP. *Bone* 19(3, Suppl):166S, 1996.
140. Pienkowski, D., McCarter, J., Doers, T., Maitra, R., Monier–Faugere, M.C., Malluche, H.H.: Bone mineral density compares and contrasts with the biomechanical measurements of canine bone. *Bone* 19(3, Suppl):159S, 1996.
141. Rastogi, R., Faugere, M.C., Geng, Z., Bogнар, B., Malluche, H.H.: Cyclosporin does not induce bone loss but enhances mineralization in normal and nephrectomized rats. *J Bone Miner. Res.* 12(Suppl 1):S402, 1997.

142. Geng, Z., Faugere, M.C., Pienkowski, D., Boskey, A., Malluche, H.H.: Calcitonin alters bone quality in canine bone. *J Bone Miner. Res.*12(Suppl 1):S238, 1997.
143. Qi, Q., Faugere, M.C., Langub, M.C. Jr., Malluche, H.H.: Validation of quantitative in situ hybridization histochemistry in mineralized bone. *J Bone Miner. Res.*12(Suppl 1):S410, 1997.
144. Fanti, P., Faugere, M.C., Geng, Z., Schmidt, J, Cohen, D., Malluche, H.H.: Genistein reduces bone loss in ovariectomized rats. *J Bone Miner. Res.*12 (Suppl 1):S477, 1997.
145. Langub, M.C. Jr., Faugere, M.C., Koszewski, N.J., Qi, Q., Malluche, H.H.: Early increase in osteoblastic interleukin-6 mRNA expression in ovariectomized rats. *J Bone Miner. Res.*12(Suppl 1):S332, 1997.
146. Faugere, M.C., Langub, M.C., Qi, Q., Geng, Z., Malluche, H.H.: Parathyroid hormone receptor mRNA expression in bone cells parallels bone turnover in dialyzed patients. *J Am Soc Nephrol* 8:551A, 1997.
147. Malluche, H.H., Langub, M.C. Jr., Monier-Faugere, M.C.: Pathogenesis and histology of renal osteodystrophy. *Osteoporosis Int* 7(Suppl 20):7, 1997.
148. Geng, Z.P., Faugere, M-C, Malluche, H.H.: Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs. 5th National Osteoporosis Conference, Anhui, P.R. China, 1997.
149. Geng, Z.P., Fanti, P., Faugere, M-C, Cohen, D., Malluche, H.H.: Moderately high consumption of ethanol suppresses histologic parameters of bone resorption in ovariectomized but not in sexually intact adult female rats. 82nd Fragrance Mountain Science Conference, Beijing, P.R. China, 1997.
150. Faugere, M.C., Langub, M.C., Qi, Q., Malluche, H.H.: Normal PTH/PTHrP receptor mRNA and protein in osteoblasts of patients with adynamic bone disease *J. Am. Soc. Nephrol.* 9:544A, 1998.
151. Langub, M.C., Faugere, M.C., Qi, Q., Malluche, H.H.: Positive feed-forward regulation of PTH/PTHrP receptors in dialyzed patients with high turnover bone disease. *J. Am. Soc. Nephrol.* 9:547A, 1998.
152. Rastogi, S., Geng, Z., Faugere, M.C., Malluche, H.H.: Tacrolimus induces bone loss by increasing bone turnover and bone resorption. *J. Am. Soc. Nephrol.* 9:714A, 1998.
153. Chu, P., Faugere, M.C., Malluche, H.H.: Bone loss in renal failure due to bone lead accumulation at low serum levels. *J. Am. Soc. Nephrol.* 9:68A, 1998.
154. Pienkowski, D., Doers, T., Maitra, R., Faugere, M.C., Malluche, H.H.: BMD predicts the maximum compressive load-bearing properties of vertebrae, but not the maximum torque-bearing properties of long bones. *Bone* 23(5):S437, 1998.
155. Langub, M.C., Qi, Q., Faugere, M.C., Malluche, H.H.: High serum PTH levels do not downregulate PTH/PTHrP receptors in osteoblasts in dialyzed patients. *Bone* 23(5):S576, 1998.
156. Puleo, D.A., Langub, M.C., Koszewski, N.J., Faugere, M., Malluche, H.H.: Less

- inhibitory and antiproliferative effects of 24-epi-D₂ than 1,25(OH)₂D₃ on bone marrow stromal cells of aged rats. *Bone* 23(5):S418, 1998.
157. Zhao, G., Faugere, M.C., MALLUCHE, H.H., Wang, J., Nakayama, T., Pike, J., Fagin, J., Clemens, T.: Osteoblast-specific overexpression of IGF-1 in transgenic mice increases cancellous bone volume. *Bone* 23(5):S172, 1998.
 158. Langub, M.C., Faugere, M.C., Malluche, H.H.: Presence of mRNA for PTH receptors in human osteoclasts with evidence for translation to its protein in pathologic but not normal condition. *J Bone Miner Res* 14(Suppl 1):F154, 1999.
 159. Faugere, M.C., Qi, Q., Mawad, H., Malluche, H.H.: Bone disease after kidney transplantation: high prevalence of low bone turnover and delayed mineralization. *J Bone Miner Res* 14 (Suppl 1):F423, 1999.
 160. Faugere, M.C., Mawad, H., Friedler, R.M., MALLUCHE, H.H.: High prevalence of low bone turnover and delayed mineralization in patients after kidney transplantation. *J Am Soc Nephrol* 10:756A 1999.
 161. Langub, M.C., Faugere, M.C., Malluche, H.H.: Relationship of PTH/PTHrP receptor expression with erosion depth in individuals with elevated serum PTH levels. Submitted to the VIIth Congress of the International Society of Bone Morphometry, 1999.
 162. Malluche, H.H., Geng, Z., Qi, Q., Faugere, M.C.: Comparison between continuous and intermittent therapy with the bisphosphonate ibandronate on bone volume, bone turnover and mineral properties in dogs after cessation of ovarian function. Submitted to the VIIth Congress of the International Society of Bone Morphometry, 1999.
 163. Mawad, H., Faugere, M.C., Qi, Q., Friedler, R.M., Malluche, H.H.: Post-transplant bone disease: Histologic assessment in 57 patients. Submitted to the VIIth Congress of the International Society of Bone Morphometry, 1999.
 164. Geng, Z., Faugere, M.C., Bauss, F., Malluche, H.H.: The bisphosphonate ibandronate increases bone volume and decreases bone resorption and bone turnover in experimental renal failure in rats. Submitted to the VIIth Congress of the International Society of Bone Morphometry, 1999.
 165. Clemens, T., Zhao, G., Faugere, M.C., Langub, C., Wang, J., Nakayama, T., Pike, J., Fagin, J., Malluche, H.: Transgenic approaches for studying IGF action in bone. Submitted to the VIIth Congress of the International Society of Bone Morphometry, 1999.
 166. Vasconez, H., Fink, B., Qi, Q., Faugere, M.C., Malluche, H.H.: Effects of two new demineralized matrices on healing of craniofacial defects. Submitted to the VIIIth Congress of International Society of Bone Morphometry, 1999.
 167. Bader, SM, Faugere, MC, Beeman, CS, Laine-Alava, MT. Fluoride stimulation of midpalatal bone formation in palatal expansion of rats. Submitted to the Southern Association of Orthodontists, 1999.
 168. Langub M.C., Tondravi M., Monier-Faugere M., Malluche H.H.: Demonstration of osteoprotegerin-ligand expression in normal bone and in patients with increased bone

- resorption. *J Bone Min Res* 15:S493, 2000.
169. Sawaya, P., Butros, R. Monier-Faugere, M.C., Geng, Z., Fanti, P., Malluche, H.H.: Bone turnover in patients with ESRD and moderately elevated serum parathyroid hormone (PTH): evidence for the usefulness of evaluating the trend in PTH. *J Am Soc Nephrol* 11:582A, 2000.
 170. Monier-Faugere MC, Geng Z, Gao P, Cantor T, Malluche HH The 1-84:7-84 PTH ratio for determination of bone turnover in chronically dialyzed patients. *J Am Soc Nephrol* 11:554A, 2000.
 171. Langub, M.C., Tondravi, M., Monier-Faugere, M.C., Malluche, H.H.: Increased osteoprotegerin-ligand expression in bone of patients with renal osteodystrophy. *J Am Soc Nephrol* 11:555A, 2000.
 172. Coco M., Glicklich D., Burris L., Durkin P., Tellis V., Greenstein S., Schechner R., McDonough P., Figueroa K., Faugere M., Malluche H.: Effect of pamidronate on bone biochemical parameters in renal transplant recipients. *J Am Soc Nephrol* 11:561A, 2000.
 173. Malluche, H.H., Mawad, H., Faugere, M.C.: Renal bone disease post-transplantation. Submitted to Transplant Bone Disease Meeting, XVIII International Congress of the Transplantation Society, 2000.
 174. Faugere, M.C., Langub, M.C., Malluche, H.H.: PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone turnover in rats. *J. Bone Min. Metab.*, 16, S546, 2001.
 175. Zhang, M., Xuan, S., Bouxsein, M.L., von Stechow, D., Faugere, M., Malluche, H., Zhao, G., Rosen, C.J., Efstratiadis, A., Clemens, T.L.: Conditional mutagenesis of the IGF1 receptor gene in osteoblasts reduces cancellous bone volume and increases bone turnover. *J. Bone Min. Metab.*, 16, S160, 2001.
 176. Zhang, M., Faugere, M., Malluche, H., Rosen, C.J., Chernausek, S.V., Clemens, T.L.: Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice results in global growth retardation. *J. Bone Min. Metab.*, 16, S478, 2001.
 177. Faugere, M.C. Langub M.C., Malluche H.H.: The effects of PTH-(1-84) on bone turnover are antagonized by PTH-(7-84) in thyroparathyroidectomized and nephrectomized rats. *J Am Soc. Nephrol*, 12, 764A, 2001.
 178. Bognar I., Coco, M., Glicklich, D., Burris, L., Durkin, P., Tellis, V., Greenstein, S., Schenar, R., McDonough, P., Figueroa, K., Faugere, M.C., Malluche, H.: Randomized trial of IV pamidronate to ameliorate bone loss in renal transplant recipients. *New York Society of Nephrology*, 2001.
 179. Sawaya, B.P., Monier-Faugere, M.C., Butros, R., Geng Z., Mawad H., Friedler, R.M, Fanti P., Malluche, H.H.: Intact parathyroid hormone levels are not predictive of bone turnover in African-American patients with ESRD. *J Am Soc. Nephrol*, 12, 772A, 2001
 180. M. Coco, D. Glicklich, I. Bognar, L. Burris, P. Durkin, V. Tellis, S. Greenstein, R. Schechner, P. McDonough, K. Figueroa, M.C. Faugere, H. Malluche: Randomized Trial of IV Pamidronate to Ameliorate Bone Loss in Renal Transplant (RT) Recipients. *J Am Soc. Nephrol*, 12, 927A, 2001

181. Faugere MC, Zhang M, Bouxsein ML, Malluche HH, Efstatiadis A, Clemens TL: Conditional mutagenesis of the IGF-1 receptor gene in osteoblasts reveals an essential role of IGF-1 in mineralization, IXth Congress of International Society of Bone Morphometry, Edinburgh, 2002.
184. Coco M, Glicklich D, Burris L, Bogнар I, Tellis V, Greenstein S, Schechner R, Wang G, Faugere MC, Malluche HH: Prospective Randomized Trial of IV Pamidronate in Renal Transplant Recipients: 6 and 12 Month Follow-Up. *J Am Soc Nephrol*, 13, 10A, 2002.
185. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne D, Kaplan M, Baker N, McCary LC, Turner SA, Goodman WG: Cinacalcet HCl reduces bone turnover and fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). World Congress of Nephrology, Berlin, 2003.
186. Sawaya BP, Monier-Faugere MC, Friedler RF, Malluche HH: Racial Differences in Bone Response to Calcitriol Therapy in ESKD Patients. *J Am Soc Nephrol* 14: 202A, 2003.
187. Coco M, Feingold R, Faugere MC, Durkin P, Negolescu O, Wang G, Malluche HH: Use of Pamidronate in ESRD Patients with Calcium Phosphate Product Prohibitive for Vitamin D Treatment. *J Am Soc Nephrol* 14: 470A, 2003.
188. Monier-Faugere MC, Mawad H, Trueba D, Friedler RF, Malluche HH: Opposite Effects of Calcitriol and Paricalcitol on the PTH-(1-84)/C-Large Fragment Ratio in Patients on Hemodialysis. *J Am Soc Nephrol*, 14, 686A, 2003.
189. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne D, Kaplan M, Baker N, McCary LC, Turner SA, Goodman WG: Cinacalcet HCl reduces bone turnover and fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). ERA-EDTA, 218, 2003.
190. Malluche HH, Faugere, MC, Wang, G, Finn, WF: Lanthanum Carbonate and Bone: No Adverse Effects Observed after 1 Year of Treatment in a Randomized, Comparator-Controlled Trial, *J Am Soc of Nephrol*, 15, 271A, 2004.
191. Malluche. H.H., Faugere, MC., Wang G., Damment S., Webster, I. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. *J Am Soc Nephrol* 15: 270A, 2004
192. Mawad, WH, Faugere, MC, Sawaya, BP, Malluche, HH. Acute parathyroid hormone response to change in serum phosphorus in African-Americans is different from response in Caucasians. *J. Amer. Soc. Nephrol*, 15, 861A, 2004
193. Faugere, MC, Koszewski, NJ, Wang, G, MALLUCHE HH. PTH 7-84 Induces Increased iPTH Levels and Increased Number but Decreased Activity of Osteoblasts. *J Am Soc of Nephrol*, 16, 32A, 2005.
194. Williams, X. Liu, C.R. Zylstra, K. Bruxvoort, M-C Faugere, M.L. Bouxsein, and T.L. Clemens: Mice lacking PTEN in Osteoblasts Have Markedly Increased Bone Volume. *J Bone Min Res*, 2005

195. Mawad, HW, Faugere, MC, MALLUCHE, HH. Effect of Phosphate Binders on Intact PTH, PTH 1-84, and the PTH/Large C Terminal PTH Peptide Ratio. *J Am Soc of Nephrol*, 16:280A, 2005.
196. Femhi, H, Osman Y, Nugyen K, Bhat S, Yee J, Faugere MC, Malluche HH. Assessment of Bone Turnover in African American Patients with CKD-5. *J Am Soc of Nephrol*, 16: 493A, 2005.
197. de Villier WJS, Garvy B, Nagy TR, Safadi FF, Malluche, HH, Faugere MC, Williams JP. Osteopetrosis in Oxidized LDL Receptor (SR-A) Knockout Mice. *J Bone Miner Res*, 2005
198. Ferreira A, Frazao JM, Faugere MC, Mueller R, Malluche HH. Effects of Sevelamer Hydrochloride and Calcium Carbonate on Bone Mineralization and Turnover in Haemodialysis Patients: A One-Year Randomized, Open-Label Bone Biopsy Study. *Nephrol Dial Trans*, 21, suppl iv, 293, 2006
199. Adragao T, Ferreira A, Frazao JM, Gil, C, Oliveira C., Sarmiento J, Ribero S, Dickson J., Carvahlo B., Rodrigues I, Baldai J, Faugere, MC, and HH Malluche. Vascular Calcifications and bone turnover in hemodialysis patients. *Nephrol Dial Trans*, 21, suppl iv, 292, 2006
200. Ferreira A, Frazao JM, Faugere MC, Mueller R, Malluche H. High prevalence of adynamic bone disease in hemodialysis patients despite adherence to K-DOQI guidelines. *NEXUS*, June 2006.
201. Porter D, Wang G, Faugere MC, Rosenblum W, Pienkowski D and H Malluche. Bone turnover and mineral quality in chronic kidney disease. Submitted to *Ortho. Res. Soc.* July 2006
202. Asci G, Ok E, Kircelli F, Sevinc Gunay E, Duman S, Ozkahya M, Toz, H, Faugere MC, and Malluche H. Predominance of adynamic bone disease in hemodialysis patients. *National Turkish Society of Nephrology*, Sept. 2006.
203. Porter D, Wang G, Faugere MC, Rosenblum W, Pienkowski D and H Malluche. Bone turnover and mineral quality in renal bone disease. Submitted to *Int. Soc Bone Morphometry*. July 2006
204. Monier-Faugere M. C, Mawad H, and H. H. Malluche. 24 hour PTH activity is higher in African American than Caucasian patients on Chronic Hemodialysis. *J. Am. Soc. Nephrol*, 17, 785A, 2006.
205. Adragao, T, Ferreira A., Frazao J., Gil, C., Oliveira C., Galvao J., Sarmetno M., Ribeiro S., Dickson, J., Carvalho B., Rodrigues, I., Baldia J., Pereira O., Faugere, M.C. and H.H. Malluche. Bone mineral density, bone histomorphometric analysis and vascular calcifications in hemodialysis patients. *Nephrol Dial Transplant*, 21, iv, 293, 2006
206. Gulay, A., Mehmet, O., Soner, D., Huseyin T., Recep, S., Meral, K., Gulperi, C., Sureyya S., Basci, A., Monier- Faugere M.C., Malluche H.H. and E. Ok The link between cardiovascular and bone disease in hemodialysis patients. *Nephrol Dial Transplant*, 22, vi, 217, 2007

207. Malluche HH, Porter DS, Monier-Faugere MC, Pienkowski D. The Importance of Bone Quality in Patients with Renal Osteodystrophy. *J Amer Soc Neph* 18: 303A, 2007.
208. Chami, A, Faugere MC, Lee, JS, Wang, G, Cantor, T, Malluche, HH. Diagnosis of bone turnover by iPTH and PTH (1-84)/C-terminal fragments ratio (PTH ratio) in African American and Caucasian patients with chronic kidney disease stage 5. *J Amer Soc Neph* 18: 302A, 2007
209. Herberth, Z, Mawad, H, Faugere, MC, Cantor, T, Herberth, J, Malluche, HH. Comparison of 6 Commonly Used Parathyroid Hormone (PTH) Assays for diagnosis of bone turnover in hemodialysis patients. *J Amer Soc Neph* 18: p305A, 2007
210. Porter, D, Faugere, M, Pienkowski, D, Malluche, HH. Gender related differences in bone mineral quality. *J Bone Min Res*, 22, Suppl 1, S309, 2007
211. Malluche HH, Lee J, Wang G, Herberth J, Monier-Faugere MC. Usefulness of the new TMV classification of renal osteodystrophy. *J Amer Soc Nephrol*, 19, 38A-39A, 2008.
212. Adragao T, Herberth J, Monier-Faugere MC, Branscum A, Malluche HH. Can dual energy X-ray absorptiometry predict bone mass in patients on chronic hemodialysis? *J Amer Soc Nephrol*, 19, 512A, 2008.
213. Asci G, Kircelli F, Sevinc E, Bozkurt D, Duman S, Ozkahya M, Toz H, Monier-Faugere MC, Malluche HH, Ok E. Bone Markers for Non-Invasive Diagnosis of Adynamic Bone Disease In Hemodialysis Patients. *J Amer Soc Nephrol*, 19, 4A-5A, 2008.
214. Lomashvili K, Malluche H, Faugere MC, O'Neill C. Bisphosphonates Inhibit Vascular Calcification and Bone Formation in Uremic Rats. *J Amer Soc Nephrol*, 19, 39A, 2008.
215. Pienkowski D, Porter D, Fauger MC, Malluche HH. Difference in bone Mineral Quality Between Caucasians and African Americans. *Ortho Res Soc*, 2008.
216. Ok E, Asci G, Ceylan N, Duman S, Ozkahya M, Toz H, Faugere MC, Malluche HH. Reduction of Calcium Exposure Slows Down Progression of Vascular Calcification and Improves Adynamic Bone Disease. Special late breaking news presentation. *Amer Soc Nephrology*, Philadelphia, November, 2008.

Grant Activity:

Funded

NIH

Effects of Vitamin D Metabolites and PTH on Bone

9/82–8/85 AM32467

Co–investigator

Shriners Hospital

Prevention of Aluminum Intoxication in Renal Osteomalacia and

Rickets 1/85–12/90 #15951

Co–Principal Investigator

NIH

Aluminum in Bone and Muscle in Uremia

9/84–8/88 RO1 DK34419

Co–investigator

NIH

Bone Loss after Ovariectomy: Response to Estrogen

4/86–3/89 RO1 AR35837

Co–investigator

Shriners Hospital for Crippled children

Prevention of Renal Rickets and Osteodystrophy with Oral Pulse or
Intravenous 1,25(OH)2D3

1/91–12/94

Co–Principal Investigator

NIH

Bone Loss after Ovariectomy

4/91–3/95 2RO1AR35837–04A2

Co–Investigator

Shriners Hospital for Crippled Children

Metabolic Bone Disease Associated with Pathological Fractures in
Nonwalking Children with Spina Bifida and Static Encephalopathy

1/91–12/94

Co–Investigator

Physician's Service Plan Award

Mechanisms of Bone Loss after Cessation of Ovarian Function

9/91–6/92

Principal Investigator

Association for Medical Research

Diuretics and Bone Quality

1/15/92–1/14/93

Principal Investigator

PSP—University of Kentucky—Dr. P. Sawaya

Vitamin D bioactivity in mild renal failure

4/1/93–3/31/94

Co–Investigator

NSF

Acquisition of a digital electronic control system for servo–hydraulic biomaterials test
system—PI: David Pienkowski, PhD

6/1/94–5/30/95 #9411945

Co–Investigator

NIH

Effect of Progestogen on Bone and Cognition in Menopause

12/1/93–11/30/98

PI: James Liu, University of Cincinnati

Co–PI: Hartmut H. Malluche, MD

Co–PI: Marie Claude Faugere, MD

NIH

Renal Bone Disease
8/1/96–7/31/00 #1 RO1 DK51530–01
PI: Hartmut H. Malluche, MD
Co-Investigator: Marie–Claude Faugere, MD
VA

Biology of IGF–1 in Bone
10/1/98-9/30/2003
PI: T.L. Clemens, University of Cincinnati
Consultant Collaborators: Hartmut H. Malluche, MD, Marie–Claude Faugere, MD
NIH

Renal Bone Disease
8/1/01-7/31/05
PI H.H. Malluche, MD
Co-Investigator, Marie-Claude Faugere, MD

NIH/NCRR
12/01/01-11/30/06
General Clinical Research Center
PI: Emery Wilson, MD
Core co-director: Marie-Claude Faugere, MD

Kentucky Nephrology Research Trust, Inc

Studies on relationships between circulating parathyroid hormone levels, bone and mineral metabolism, and vitamin D treatment in African American, Caucasian, diabetic, and non diabetic patients on chronic maintenance dialysis.
12/1/2004-11/30/2008 PI Marie-Claude Faugere, MD

NIH
Renal Osteodystrophy: A fresh approach
8/1/08-7/31/13 PI H.H. Malluche, MD
Co-Investigator, Marie-Claude Faugere, MD

Industry Funded—Completed

Shire Pharmaceuticals -- Effects of Lanthanum Carbonate Compound with Calcium Carbonate on Renal Bone Disease in Chronic Renal Failure Patients Receiving Dialysis
11/00 - 2005
PI: Hartmut H. Malluche, MD, Co-investigator: Marie-Claude Faugere, MD

Amgen Inc. – Effects of an Oral Calcimimetic Agent on Renal Bone Disease in Hemodialysis Patients with Secondary Hyperparathyroidism
3/02–3/05 –PI: Hartmut H. Malluche, MD, Co-investigator: Marie-Claude Faugere, MD

GeTex Pharmaceuticals/Genzyme Europe – Effects of Sevelamer Hydrochloride & Calcium Carbonate on Bone Turnover & Mineralization in Hemodialysis Patients
6/02–2005 –PI: Hartmut H. Malluche, MD, Co-investigator: Marie-Claude Faugere, MD

Submitted

Kentucky Nephrology Research Trust, Inc

Renal Osteodystrophy

12/1/2008-11/30/2012 PI Marie-Claude Faugere, MD